Skip to main content

Table 1 Baseline characteristics

From: Impact of glycemic control status on patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention

CharacteristicGroup 1 (174)Group 2 (64)Group 3 (112)
Age (years)59.34 ± 11.7161.61 ± 12.8564.29 ± 10.84 #
Male (%)149 (85.6%)52 (81.3%)80 (71.4%)#
Prior CHD (%)30 (17.2%)15 (23.4%)30 (26.8%)
Hypertension (%)80 (46%)43 (67.2%)#66 (58.9%)#
Prior Stroke (%)16 (9.2%)9 (14.1%)13 (11.6%)
Prior PCI (%)12 (6.9%)8 (12.5%)15 (13.3%)
Multivessel disease90 (51.8%)42 (65.6%)88 (78.6%)#
Killip class 3–4 (%)8 (4.6%)3 (4.6%)12 (10.7%) #
Laboratory results
 Glucose (mmol/L)5.69
(5.05–6.60)
6.65 #
(6.15–7.97)
11.11 # *
(7.85–13.76)
 HbA1c (%)5.60
(5.30–5.90)
6.60 #
(6.10–6.90)
7.80 # *
(7.30–9.58)
 Hemoglobin(g/L)148.63 ± 15.05144.94 ± 16.58143.36 ± 17.26#
 TG (mmol/L)1.46
(1.07–2.04)
1.51
(1.04–2.10)
1.70 # *
(1.22–2.30)
 HDL-C (mmol/L)1.24
(0.99–1.47)
1.23
(0.99–1.46)
1.20
(0.99–1.43)
 LDL-C (mmol/L)2.72
(2.20–3.33)
2.73
(2.22–3.35)
2.77
(2.26–3.35)
 Apo AI (g/L)1.14
(0.96–1.33)
1.17
(0.99–1.35)
1.17
(1.01–1.24)
 Apo B (g/L)0.84
(0.68–0.97)
0.85
(0.69–0.97)
0.88 # *
(0.79–1.02)
 Creatinine(umol/L)68.00
(61.00–78.25)
68.50
(61.00–80.75)
67.50
(57.00–79.75)
Long-term medication before admission
 Aspirin21 (12.5%)17 (27.4%)#20 (17.9%)
 Clopidogrel12 (7.1%)7(11.3%)11 (9.8%)
 Statin11 (6.5%)9 (14.5%)16 (14.2%)
 Beta-blocker16 (9.5%)12 (19.4%)#21 (18.8%)#
 ACEI11 (6.5%)5 (8.1%)17 (15.1%) #
Medication in hospital
 Insulin19(10.9%)10(15.6%)63(56.3%) # *
 Beta-blocker155(89.1%)58(90.6%)101(90.2%)
 ACEI155(89.1%)62(96.9%)106(94.6%)
  1. ACEI angiotensin converting enzyme inhibitor, Apo AI apolipoprotein AI, Apo B apolipoprotein B, CHD coronary heart disease, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL Low-density lipoprotein, PCI percutaneous coronary intervention, TG triglyceride
  2. #P < 0.05, vs Group 1
  3. *P < 0.05, vs Group 2